Nowadays, all advanced countries in the world are doing great research on the treatment of COVID-19. In addition to studying the injection vaccine for COVID-19, oral vaccines are also being studied. It is found that oral vaccines are safer, have fewer adverse side effects, and are suitable for use by most people. According to a news report on January 28, 2022, Pfizer successfully developed an oral drug for novel pneumonia, which has been approved by the U.S. Food and Drug Administration and the European Medicines Agency. Patients, can take this drug, it can reduce the risk of hospital admission or death, the side effects are mild, and the oral drug is believed to be effective for Delta, Omicron or other variants.
There is also a technology company in Hong Kong Science Park called “DreamTec”, which has also successfully developed an oral vaccine. The scientific research team of DreamTec used Bacillus Subtilis after the SARS-CoV-2 genome was published. Oral vaccine platform for Covid-19 to rapidly develop a preventive Covid-19 vaccine health food for human use. The vaccine name is “Neutralizing Postbiotic”, it can enhance human immunity and produce neutralizing antibodies to prevent the virus from working, it contains “special protein Bacillus subtilis” combined with astragalus extract (astragalus polysaccharide), Yunzhi extract (Yunzhi Polysaccharide), Green Tea Extract (EGCG) and Chitosan Oligosaccharide (COS). Bacillus subtilis symbiotically coexists with other microorganisms in the human gut. It induces a series of immune responses in the human body and produces more immune efficacy, thereby providing protection and fighting viruses for the body. Clinical experiments have confirmed that it is effective against the new coronary pneumonia virus. The Hong Kong government has approved it to launch the market as soon as possible in the form of health products, so that people can benefit as soon as possible; of course, the review of the drug level will continue after that.
At present, although the “Neutralizing Postbiotic New Coronary Pneumonia Oral Vaccine” is launched in the market as a health care product, due to the limited production volume, large-scale marketing will not be carried out. Only a small number of stores can pick up the product and sell it. Welcome to inquire and order for trial.
